These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22334013)

  • 21. Crizotinib Resensitization by Compound Mutation.
    Bordi P; Del Re M; Tiseo M
    N Engl J Med; 2016 May; 374(18):1790. PubMed ID: 27144863
    [No Abstract]   [Full Text] [Related]  

  • 22. Crizotinib Resensitization by Compound Mutation.
    Shaw AT; Engelman JA
    N Engl J Med; 2016 May; 374(18):1790-1. PubMed ID: 27144862
    [No Abstract]   [Full Text] [Related]  

  • 23. Resistance: Crizotinib makes a comeback.
    Shipman L
    Nat Rev Cancer; 2016 Feb; 16(2):69. PubMed ID: 26797648
    [No Abstract]   [Full Text] [Related]  

  • 24. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.
    Saraceni C; Li PM; Gainor JF; Stopyra GA; Friedman EL
    J Thorac Oncol; 2015 Jul; 10(7):1116-7. PubMed ID: 26134230
    [No Abstract]   [Full Text] [Related]  

  • 25. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
    Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH
    Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALK in lung cancer: past, present, and future.
    Shaw AT; Engelman JA
    J Clin Oncol; 2013 Mar; 31(8):1105-11. PubMed ID: 23401436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
    Ou SI; Lee TK; Young L; Fernandez-Rocha MY; Pavlick D; Schrock AB; Zhu VW; Milliken J; Ali SM; Gitlitz BJ
    Lung Cancer; 2017 Apr; 106():110-114. PubMed ID: 28285684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A functional landscape of resistance to ALK inhibition in lung cancer.
    Wilson FH; Johannessen CM; Piccioni F; Tamayo P; Kim JW; Van Allen EM; Corsello SM; Capelletti M; Calles A; Butaney M; Sharifnia T; Gabriel SB; Mesirov JP; Hahn WC; Engelman JA; Meyerson M; Root DE; Jänne PA; Garraway LA
    Cancer Cell; 2015 Mar; 27(3):397-408. PubMed ID: 25759024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.
    Wang HY; Ho CC; Shih JY
    J Thorac Oncol; 2017 May; 12(5):e49-e51. PubMed ID: 28434515
    [No Abstract]   [Full Text] [Related]  

  • 31. Second-generation ALK inhibitors: filling the non "MET" gap.
    Ramalingam SS; Khuri FR
    Cancer Discov; 2014 Jun; 4(6):634-6. PubMed ID: 24891360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
    Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
    Girard N; Audigier-Valette C; Cortot AB; Mennecier B; Debieuvre D; Planchard D; Zalcman G; Moro-Sibilot D; Cadranel J; Barlési F
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):225-33. PubMed ID: 25413260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer.
    Pender A; Popat S
    Ther Adv Respir Dis; 2015 Jun; 9(3):97-104. PubMed ID: 25801645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
    Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
    Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
    Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
    Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M; De Marinis F; Hirsch FR; Gridelli C
    Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
    Yi ES; Chung JH; Kulig K; Kerr KM
    Mol Diagn Ther; 2012 Jun; 16(3):143-50. PubMed ID: 22506598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].
    Zhang HJ; Zhang XT; Zhang L
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):862-4. PubMed ID: 23324244
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.